JP2010531304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010531304A5 JP2010531304A5 JP2010513237A JP2010513237A JP2010531304A5 JP 2010531304 A5 JP2010531304 A5 JP 2010531304A5 JP 2010513237 A JP2010513237 A JP 2010513237A JP 2010513237 A JP2010513237 A JP 2010513237A JP 2010531304 A5 JP2010531304 A5 JP 2010531304A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen atom
- alkyl
- chemical formula
- aralkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 72
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 102100022629 Fructose-2,6-bisphosphatase Human genes 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 94
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 85
- 239000000126 substance Substances 0.000 claims 72
- 125000003118 aryl group Chemical group 0.000 claims 64
- 125000003710 aryl alkyl group Chemical group 0.000 claims 62
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 58
- 238000000034 method Methods 0.000 claims 55
- 125000003545 alkoxy group Chemical group 0.000 claims 42
- 125000005843 halogen group Chemical group 0.000 claims 34
- 229910052760 oxygen Inorganic materials 0.000 claims 34
- 229910052717 sulfur Inorganic materials 0.000 claims 34
- 125000003282 alkyl amino group Chemical group 0.000 claims 20
- 125000004663 dialkyl amino group Chemical group 0.000 claims 20
- 101710086299 Fructose-2,6-bisphosphatase Proteins 0.000 claims 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000004429 atom Chemical group 0.000 claims 15
- 125000002252 acyl group Chemical group 0.000 claims 14
- 125000002947 alkylene group Chemical group 0.000 claims 14
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 8
- 125000003277 amino group Chemical group 0.000 claims 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 8
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 8
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 claims 7
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 claims 7
- 238000012216 screening Methods 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 4
- 125000005156 substituted alkylene group Chemical group 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 230000006692 glycolytic flux Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 1
- 0 C*(*)=*(*)*(*)C(/N=P/*=S/*)=* Chemical compound C*(*)=*(*)*(*)C(/N=P/*=S/*)=* 0.000 description 2
- 101000823463 Homo sapiens Fructose-2,6-bisphosphatase Proteins 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93603007P | 2007-06-18 | 2007-06-18 | |
| PCT/US2008/007594 WO2008156783A2 (en) | 2007-06-18 | 2008-06-18 | Family of pfkfb3 inhibitors with anti-neoplastic activities |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010531304A JP2010531304A (ja) | 2010-09-24 |
| JP2010531304A5 true JP2010531304A5 (enExample) | 2011-07-28 |
Family
ID=39735477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010513237A Pending JP2010531304A (ja) | 2007-06-18 | 2008-06-18 | 抗悪性腫瘍活性を有するｐｆｋｆｂ３阻害物質ファミリー |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8088385B2 (enExample) |
| EP (1) | EP2167058B1 (enExample) |
| JP (1) | JP2010531304A (enExample) |
| AU (1) | AU2008266856A1 (enExample) |
| WO (1) | WO2008156783A2 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| KR101660050B1 (ko) | 2008-01-04 | 2016-09-26 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
| BRPI1015135B1 (pt) | 2009-06-29 | 2021-08-03 | Incyte Holdings Corporation | Pirimidinonas inibidoras de pi3k, composição compreendendo tais compostos, bem como usos dos mesmos |
| WO2011050211A2 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| WO2011050210A1 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| WO2011075630A1 (en) * | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
| US8759359B2 (en) * | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| US9403769B2 (en) | 2010-02-22 | 2016-08-02 | Advanced Cancer Therapeutics, Llc | Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| CA2796311A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | Fused derivatives as pi3k.delta. inhibitors |
| EP3045452A1 (en) | 2010-04-22 | 2016-07-20 | Vertex Pharmaceuticals Inc. | Process of producing cycloalkylcarboxamido-indole compounds |
| WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| WO2011161201A1 (en) | 2010-06-22 | 2011-12-29 | Kancera Ab | Bisarylsulfonamides useful as kinase inhibitors in the treatment of inflammation and cancer |
| WO2012035171A2 (en) | 2010-09-17 | 2012-03-22 | Kancera Ab | New compounds |
| CA2822070C (en) | 2010-12-20 | 2019-09-17 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| GB201103762D0 (en) | 2011-03-07 | 2011-04-20 | Vib Vzw | Means and methods for the treatment of neurodegenerative disorders |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| US9492418B2 (en) | 2011-05-10 | 2016-11-15 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Inhibitors of PFKFB3 for cancer therapy |
| RU2477723C2 (ru) | 2011-06-16 | 2013-03-20 | Общество С Ограниченной Ответственностью "Фьюжн Фарма" | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе |
| GB201112145D0 (en) | 2011-07-15 | 2011-08-31 | Vib Vzw | Means and methods for the treatment of pathological angiogenesis |
| DK3513793T3 (da) | 2011-09-02 | 2021-04-26 | Incyte Holdings Corp | Heterocyclylaminer som pi3k-inhibitorer |
| JP6216326B2 (ja) | 2011-12-22 | 2017-10-18 | カンセラ・アクチエボラグ | 炎症および癌の処置において有用なビスアリールスルホンアミド |
| US10000449B2 (en) | 2011-12-22 | 2018-06-19 | Kancera Ab | Bisarylsulfonamides useful in the treatment of inflammation and cancer |
| WO2013148228A1 (en) * | 2012-03-29 | 2013-10-03 | Advanced Cancer Therapeutics, Llc | Pfkfb3 inhibitor and methods of use as an anti-cancer therapeutic |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| MX386085B (es) | 2012-11-01 | 2025-03-18 | Infinity Pharmaceuticals Inc | Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa |
| US8871754B2 (en) | 2012-11-19 | 2014-10-28 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| PL2925757T3 (pl) | 2012-11-19 | 2018-06-29 | Novartis Ag | Związki i kompozycje do leczenia chorób pasożytniczych |
| PE20160608A1 (es) | 2013-10-14 | 2016-07-08 | Eisai Randd Man Co Ltd | Compuestos de quinolina selectivamente sustituida |
| AU2014334551B2 (en) | 2013-10-14 | 2018-05-10 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| PL3925607T3 (pl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| GB201407693D0 (en) * | 2014-05-01 | 2014-06-18 | Univ Montfort | Compound |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| MX373232B (es) | 2015-02-27 | 2020-05-08 | Incyte Holdings Corp | Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparación. |
| US10881654B2 (en) | 2015-04-24 | 2021-01-05 | University Of Louisville Research Foundation, Inc. | Selective PFKFB4 inhibitors for the treatment of cancer |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016180537A1 (en) * | 2015-05-13 | 2016-11-17 | Selvita S.A. | Substituted quinoxaline derivatives |
| US20180147198A1 (en) * | 2015-05-28 | 2018-05-31 | University Of Louisville Research Foundation, Inc. | Combinations of pfkfb3 inhibitors and immune checkpoint inhibitors to treat cancer |
| WO2017208174A2 (en) * | 2016-05-31 | 2017-12-07 | The Regents Of The University Of California | Methods of treating disease with pfkfb3 inhibitors |
| BR112018077021A2 (pt) | 2016-06-24 | 2019-04-02 | Infinity Pharmaceuticals, Inc. | terapias de combinação |
| EP3651752B1 (en) | 2017-07-11 | 2024-11-20 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| US10774046B2 (en) | 2017-10-26 | 2020-09-15 | University Of Louisville Research Foundation, Inc. | Inhibitors for the treatment of cancer and related methods |
| MA52761A (fr) | 2018-06-01 | 2021-04-14 | Incyte Corp | Schéma posologique destiné au traitement de troubles liés à la pi3k |
| EP3833345B1 (en) | 2018-08-07 | 2024-07-17 | Kemijski Institut | Small molecule-inhibitors of 6-phosphofructo-1-kinase for reducing lactate generation by cancer cells |
| CN109535068B (zh) * | 2018-12-26 | 2022-07-29 | 中国药科大学 | 吡啶取代查尔酮类化合物或其可药用的盐及其制备方法和用途 |
| US12440481B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| FI4069691T3 (fi) | 2019-12-06 | 2024-11-13 | Vertex Pharma | Substituoituja tetrahydrofuraaneja natriumkanavien modulaattoreina |
| CR20230586A (es) | 2021-06-04 | 2024-05-07 | Vertex Pharma | N-(hydroxyalquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio |
| LU102863B1 (en) | 2021-10-19 | 2023-04-20 | Kemijski Inst | Small molecule-inhibitors of 6-phosphofructo-1-kinase for reducing Reactive oxygen species (ROS) generation by cancer cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| CA2395191A1 (en) * | 1999-12-23 | 2001-06-28 | Tedman Ehlers | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
| US20060035981A1 (en) | 2003-08-02 | 2006-02-16 | Mazzio Elizabeth A | Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment |
| ITMI20041869A1 (it) * | 2004-10-01 | 2005-01-01 | Dac Srl | Nuovi inibitori delle istone deacetilasi |
| CA2584485C (en) * | 2004-10-20 | 2013-12-31 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
-
2008
- 2008-06-18 AU AU2008266856A patent/AU2008266856A1/en not_active Abandoned
- 2008-06-18 EP EP08768587.1A patent/EP2167058B1/en not_active Not-in-force
- 2008-06-18 WO PCT/US2008/007594 patent/WO2008156783A2/en not_active Ceased
- 2008-06-18 JP JP2010513237A patent/JP2010531304A/ja active Pending
- 2008-06-18 US US12/141,751 patent/US8088385B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010531304A5 (enExample) | ||
| JP2011515397A5 (enExample) | ||
| JP2007191486A5 (enExample) | ||
| EA201000552A1 (ru) | Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в | |
| RU2005140570A (ru) | Фармацевтическая композиция, содержащая ингибитор гистондеацетилазы | |
| CN106167488A (zh) | 治疗癌症及非肿瘤病症的方法 | |
| JP2012524731A5 (enExample) | ||
| JP2009515890A5 (enExample) | ||
| JP2014528423A5 (enExample) | ||
| JP2011006480A5 (enExample) | ||
| JP2011509949A5 (enExample) | ||
| JP2011506274A5 (enExample) | ||
| JP2011529962A5 (enExample) | ||
| DK2979700T3 (en) | ANTITUMUM AGENT CONTAINING A LOW IRINOTECAN HYDROCHLORIDE HYDRATE | |
| JP2016512831A5 (enExample) | ||
| RU2012135093A (ru) | Производные пиразина | |
| CA2589850A1 (en) | Amide prodrug of gemcitabine, compositions and use thereof | |
| JP2020531414A5 (enExample) | ||
| EP2036903B1 (en) | Potentiator of radiation therapy | |
| JP6063472B2 (ja) | 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法 | |
| JP2008508287A5 (enExample) | ||
| JPWO2021252661A5 (enExample) | ||
| CA2483826A1 (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
| JP2007527408A5 (enExample) | ||
| WO2008106125A3 (en) | Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists |